Correction
EGFR Antagonists in Cancer Treatment
N Engl J Med 2009; 360:1579April 9, 2009
- Article
EGFR Antagonists in Cancer Treatment (Review Article, N Engl J Med 2008:358;1160 - 1174) . In Table 2 (page 1163), the information for gefitinib under Approved Uses should give the FDA approval date as May 2003. In the Clinical Efficacy of EGFR Antagonists in Human Cancers section, in the paragraph beginning “In a phase 2 study” (page 1164), the words “gefitinib or” should be deleted from the fourth and fifth sentences; only erlotinib should be named. In the next paragraph, beginning “On the basis” (page 1164), the words “or erlotinib” should be added to the third and fourth sentences after gefitinib; both gefitinib and erlotinib should be named. In the last paragraph of the section, in the penultimate sentence (page 1165), the word “binorelbine” should read “vinorelbine.” In Table 3 (page 1166), the number of patients listed under Erlotinib should be 488; the median progression-free survival should read 1.8 for placebo and 2.2 for erlotinib, with a hazard ratio (and 95% confidence interval [CI]) of 0.61 (0.51–0.74), and the median overall survival should read 4.7 for placebo and 6.7 for erlotinib, with a hazard ratio (95% CI) of 0.70 (0.58–0.85). In Table 4 (page 1167), the median overall survival for the NCIC-CO.17 trial should read 4.6 under Best Supportive Care and 6.17 under Cetuximab. The article has been corrected at NEJM.org.
- Citing Articles (1)
Citing Articles
1
Antonio Passaro, Enrico Cortesi, Filippo de Marinis. (2011) Second-line treatment of non-small-cell lung cancer: chemotherapy or tyrosine kinase inhibitors?. Expert Review of Anticancer Therapy 11:10, 1587-1597
CrossRef
